Silence Therapeutics plc (Silence Therapeutics) is a developer of therapeutics that channels gene silencing to cure life-threatening diseases. The company's pipeline products include SLN124 and SLN360. Its SLN360 is developed for the treatment of cardiovascular disease with high Lp(a) in risk of heart disease and heart stroke, and SLN124 for e-Thalassaemia and myelodysplastic syndrome. Silence Therapeutics also provides RNA interfaces that include short interfering RNA (siRNA) and messenger RNAs (mRNA). The company collaborates with pharmaceutical, biotechnology companies and academic research institutions. It operates in Germany, the US and the UK. Silence Therapeutics is headquartered in London, England, the UK.
Headquarters
United Kingdom
Address
72 Hammersmith Road, London, England, W148TH
Website
www.silence-therapeutics.com
Telephone
44 20 34576900
No of Employees
116
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SLNCF (OTC)
Revenue (2021)
$21.6M
41%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
-2.7%
(2021 vs 2020)
Market Cap*
$1.0B
Net Profit Margin (2021)
XYZ
27.1%
(2021 vs 2020)
* As of and is in US$
Silence Therapeutics Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| SLN360 – For Cardiovascular Disease |
| SLN124 - For e-Thalassaemia and Myelodysplastic Syndrome |
Competitor Comparison
| Key Parameters | Silence Therapeutics Plc | Novartis Pharmaceuticals UK Ltd | Oxford BioMedica Plc | Alnylam UK Ltd | Blueberry Therapeutics Ltd |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United Kingdom | United Kingdom |
| City | London | London | Oxford | Maidenhead | Alderley Edge |
| State/Province | England | England | England | Berkshire | Cheshire |
| No. of Employees | 116 | 869 | 891 | - | - |
| Entity Type | Public | Private | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Iain Gladstone Ross | Chairman | Executive Board | 2019 | 69 |
| Craig Tooman | Chief Executive Officer; President; Director | Executive Board | 2022 | 58 |
| Giles Victor Campion | Head-Research and Development; Chief Medical Officer; Director; Executive Vice President | Executive Board | 2020 | 69 |
| Rhonda Hellums | Chief Financial Officer | Senior Management | 2022 | 51 |
| Curtis Rambaran, MD | Chief Medical Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer